ArticleCureus2025
Association Between Cancer Stem Cell Marker Expression and Clinicopathological Features in Thai Patients With Hepatocellular Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Cancer stem cells (CSCs) are believed to play critical roles in tumor initiation, progression, metastasis, and treatment resistance. This study aimed to evaluate the expression of the four most commonly CSCs with relevant to HCC, namely, CD44, CD90, CD133, and epithelial cell adhesion molecule (EpCAM), in tumor and adjacent noncancerous tissues of Thai HCC patients and to explore their association with clinicopathological features and patient survival. Methods HCC patients undergoing curative hepatic resection at the National Cancer Institute, Thailand, were included. Tumor and matched adjacent noncancerous tissues were collected and analyzed for the expression of CD44, CD90, CD133, and EpCAM using immunohistochemistry (IHC). IHC scores were calculated based on staining intensity and extent. Associations between marker expression and clinicopathological features were assessed, and overall survival was analyzed using the Kaplan-Meier method. Results All four CSC markers were significantly overexpressed in tumor tissues compared to adjacent normal tissues (P < 0.05). However, no statistically significant associations were found between marker expression and clinicopathological parameters. Kaplan-Meier analysis showed no significant differences in overall survival between high and low expression groups. Nonetheless, patients with low CD44 and CD133 expression tended to have better survival outcomes, although not statistically significant. Conclusion The findings suggest that CD44, CD90, CD133, and EpCAM were enriched in HCC tumor tissues, supporting their role in hepatocarcinogenesis. However, no strong correlations were found with clinical features or survival in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.